<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30326889</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2466</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>BMC pulmonary medicine</Title><ISOAbbreviation>BMC Pulm Med</ISOAbbreviation></Journal><ArticleTitle>Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report.</ArticleTitle><Pagination><StartPage>162</StartPage><MedlinePgn>162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12890-018-0727-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Until recently, lung transplantation was not considered in patients with human immunodeficiency virus (HIV). HIV seropositive patients with suppressed viral loads can now expect long-term survival with the advent of highly active antiretroviral therapies (HAART); however, HIV remains a relative contraindication to lung transplantation. We describe, to our knowledge, the first HIV seropositive lung transplant recipient in Canada. We also review the literature of previously reported cases of solid-organ transplantation in patients with HIV with a focus on immunosuppression considerations.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 48-year old man received a bilateral lung transplant for a diagnosis of desquamative interstitial pneumonia (DIP) attributed to cigarette and cannabis smoking. His control of HIV infection pre-transplant was excellent on HAART, and he had no other contraindications to lung transplantation. The patient underwent bilateral lung transplantation using basiliximab, methylprednisolone, and mycophenolate mofetil (MMF) as induction immunosuppression. He was maintained on MMF, prednisone, and tacrolimus thereafter, and restarted his HAART regimen immediately post-operatively. His post-transplant course was complicated by Grade A1 minimal acute cellular rejection, as well as an enterovirus/rhinovirus graft infection. Despite these complications, his functional status and control of HIV infection remain excellent 24&#xa0;months post-transplant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our patient is one of only several HIV seropositive lung transplant recipients reported globally. With growing acceptance of transplantation in this population, there is a need for clarification of prognosis post-transplantation, as well as optimal immunosuppression regimens for these patients. This case report adds to the recent literature that suggests HIV seropositivity should not be considered a contraindication to lung transplantation, and that post-transplant patients with HIV can be managed safely with basiliximab, tacrolimus, MMF and prednisone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of British Columbia, 2775 Laurel Street, 10th Floor, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Lung Transplant Program, Vancouver General Hospital, 2775 Laurel Street, 5th Floor, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Respirology, Department of Medicine, University of British Columbia, 2775 Laurel Street, 7th Floor, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Thoracic Surgery, Department of Surgery, University of British Columbia, 950 West 10th Avenue, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Partovi</LastName><ForeName>Nilu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of British Columbia, 217 - 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Churg</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vancouver Coastal Health Research Institute, University of British Columbia, 2635 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of British Columbia, Room G227 - 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St. Paul's Hospital, Room 166 - 1081 Burrard Street, Ward 8B, Vancouver, BC, V6Z 1Y6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rom&#xe9;o</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, University of Montreal, 1051 Sanguinet Street, Montreal, QC, H2X 3E4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalaoui</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiology, Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, University of Montreal, 1051 Sanguinet Street, Montreal, QC, H2X 3E4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nador</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lung Transplant Program, Vancouver General Hospital, 2775 Laurel Street, 5th Floor, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Respirology, Department of Medicine, University of British Columbia, 2775 Laurel Street, 7th Floor, Vancouver, BC, V5Z 1M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Alissa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of British Columbia, 452D - 2733 Heather Street, Vancouver, BC, V5Z 3J5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manganas</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Respirology, Department of Medicine, Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, 1051 Sanguinet Street, Montreal, QC, H2X 3E4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryerson</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0003-1049-393X</Identifier><AffiliationInfo><Affiliation>Lung Transplant Program, Vancouver General Hospital, 2775 Laurel Street, 5th Floor, Vancouver, BC, V5Z 1M9, Canada. chris.ryerson@hli.ubc.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Heart Lung Innovation, St. Paul's Hospital, Room 166 - 1081 Burrard Street, Ward 8B, Vancouver, BC, V6Z 1Y6, Canada. chris.ryerson@hli.ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pulm Med</MedlineTA><NlmUniqueID>100968563</NlmUniqueID><ISSNLinking>1471-2466</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C562470">Interstitial Pneumonitis, Desquamative, Familial</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030342" MajorTopicYN="N">Genetic Diseases, Inborn</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006679" MajorTopicYN="N">HIV Seropositivity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016040" MajorTopicYN="Y">Lung Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Desquamative interstitial pneumonia</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Lung transplant</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR PUBLICATION: This case report details information regarding a human patient, and was reported with the express written consent of this patient. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30326889</ArticleId><ArticleId IdType="pmc">PMC6191892</ArticleId><ArticleId IdType="doi">10.1186/s12890-018-0727-0</ArticleId><ArticleId IdType="pii">10.1186/s12890-018-0727-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014&#x2014;an update from the pulmonary transplantation Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2015;34(1):1&#x2013;15. doi: 10.1016/j.healun.2014.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2014.06.014</ArticleId><ArticleId IdType="pubmed">25085497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertani A, Grossi P, Vitulo P, DAncona G, Arcadipane A, Costa AN, et al. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. Am J Transplant. 2009;9(9):2190&#x2013;2196. doi: 10.1111/j.1600-6143.2009.02779.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2009.02779.x</ArticleId><ArticleId IdType="pubmed">19656132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern RM, Seethamraju H, Blanc PD, Sinha N, Loebe M, Golden J, et al. The feasibility of lung transplantation in HIV-seropositive patients. Ann Am Thoracic Soc. 2014;11(6):882. doi: 10.1513/AnnalsATS.201402-083OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201402-083OC</ArticleId><ArticleId IdType="pmc">PMC4213997</ArticleId><ArticleId IdType="pubmed">24964265</ArticleId></ArticleIdList></Reference><Reference><Citation>Koval C, Malinis M, Mueller N, Krisl J, Hannan M, Grossi P, et al. Heart and lung transplantation outcomes in HIV-positive recipients. HOBOKEN: WILEY; 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">31636044</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation. 1999;68(2):307&#x2013;309. doi: 10.1097/00007890-199907270-00027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-199907270-00027</ArticleId><ArticleId IdType="pubmed">10440408</ArticleId></ArticleIdList></Reference><Reference><Citation>Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipients. Fundam Clin Pharmacol. 2009;23(4):423&#x2013;425. doi: 10.1111/j.1472-8206.2009.00706.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-8206.2009.00706.x</ArticleId><ArticleId IdType="pubmed">19709321</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain AKB, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl. 2002;8(9):841&#x2013;845. doi: 10.1053/jlts.2002.34880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jlts.2002.34880</ArticleId><ArticleId IdType="pubmed">12200788</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z, Kane BM, Petty LA, Josephson MA, Sutor J, Pursell KJ. Cobicistat significantly increases tacrolimus serum concentrations in a renal transplant recipient with human immunodeficiency virus infection. Pharmacother J Hum Pharmacol Drug Ther. 2016;36(6):e53. doi: 10.1002/phar.1752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1752</ArticleId><ArticleId IdType="pubmed">27041642</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazelaar HD, Wright JL, Churg A. Desquamative interstitial pneumonia. Histopathology. 2011;58(4):509&#x2013;516. doi: 10.1111/j.1365-2559.2010.03649.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2559.2010.03649.x</ArticleId><ArticleId IdType="pubmed">20854463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report&#x2014;2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1037&#x2013;1046. doi: 10.1016/j.healun.2017.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2017.07.019</ArticleId><ArticleId IdType="pubmed">28779893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ag&#xfc;ero F, Castel MA, Cocchi S, Moreno A, Mestres CA, Cervera C, et al. An update on heart transplantation in human immunodeficiency virus-infected patients: heart transplantation in HIV-infected patients. Am J Transplant. 2016;16(1):21&#x2013;28. doi: 10.1111/ajt.13496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13496</ArticleId><ArticleId IdType="pubmed">26523614</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu JX, Terasaki PI, Waki K, Cai JC, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation. 2006;81(12):1658&#x2013;1661. doi: 10.1097/01.tp.0000226074.97314.e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.tp.0000226074.97314.e0</ArticleId><ArticleId IdType="pubmed">16794531</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004&#x2013;2014. doi: 10.1056/NEJMoa1001197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1001197</ArticleId><ArticleId IdType="pmc">PMC3028983</ArticleId><ArticleId IdType="pubmed">21083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS. 2011;25(6):777&#x2013;786. doi: 10.1097/QAD.0b013e328344febb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e328344febb</ArticleId><ArticleId IdType="pubmed">21412058</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355&#x2013;365. doi: 10.1111/j.1600-6143.2007.02061.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2007.02061.x</ArticleId><ArticleId IdType="pubmed">18093266</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland ME, Barin B, Huprikar S, Murphy B, Hanto DW, Blumberg E, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS. 2016;30(3):435&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4957135</ArticleId><ArticleId IdType="pubmed">26765937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HP, Kaczorowski DJ, Basu A, Khan A, McCauley J, Marcos A, et al. Living-related donor renal transplantation in HIV plus recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation. 2004;78(11):1683&#x2013;1688. doi: 10.1097/01.TP.0000145880.38548.0D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TP.0000145880.38548.0D</ArticleId><ArticleId IdType="pmc">PMC2979320</ArticleId><ArticleId IdType="pubmed">15591960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazuecos A, Fernandez A, Zarraga S, Andres A, Rodriguez-Benot A, Jimenez C, et al. High incidence of delayed graft function in HIV-infected kidney transplant recipients. Transplant Int. 2013;26(9):893&#x2013;902. doi: 10.1111/tri.12147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.12147</ArticleId><ArticleId IdType="pubmed">23841527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucirka LM, Durand CM, Bae S, Avery RK, Locke JE, Orandi BJ, et al. Induction immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus. Am J Transplant. 2016;16(8):2368&#x2013;2376. doi: 10.1111/ajt.13840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.13840</ArticleId><ArticleId IdType="pmc">PMC4956509</ArticleId><ArticleId IdType="pubmed">27111897</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S, et al. CD4 lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med. 1993;118(9):674&#x2013;680. doi: 10.7326/0003-4819-118-9-199305010-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-118-9-199305010-00003</ArticleId><ArticleId IdType="pubmed">8096373</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Villar S, Moreno S, Fuentes-Ferrer M, S&#xe1;nchez-Marcos C, &#xc1;vila M, Sainz T, et al. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Medicine. 2014;15(1):40&#x2013;49. doi: 10.1111/hiv.12081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hiv.12081</ArticleId><ArticleId IdType="pubmed">24007533</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Villar S, Guti&#xe9;rrez C, Vallejo A, Hern&#xe1;ndez-Novoa B, D&#xed;az L, Abad Fern&#xe1;ndez M, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 2013. 2012;66(1):57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046968</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller TF, Grebe SO, Neumann MC, Heymanns J, Radsak K, Sprenger H, et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation. 1997;64(10):1432. doi: 10.1097/00007890-199711270-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-199711270-00010</ArticleId><ArticleId IdType="pubmed">9392307</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4 T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006;6(4):753&#x2013;760. doi: 10.1111/j.1600-6143.2006.01238.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2006.01238.x</ArticleId><ArticleId IdType="pubmed">16539632</ArticleId></ArticleIdList></Reference><Reference><Citation>Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76(2):370&#x2013;375. doi: 10.1097/01.TP.0000075973.73064.A6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TP.0000075973.73064.A6</ArticleId><ArticleId IdType="pubmed">12883195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachem RR, Edwards LB, Yusen RD, Chakinala MM, Alexander Patterson G, Trulock EP. The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation registry. Clin Transpl. 2008;22(5):603&#x2013;608. doi: 10.1111/j.1399-0012.2008.00831.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0012.2008.00831.x</ArticleId><ArticleId IdType="pubmed">18435784</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplant J. 2014;97(4):446&#x2013;450. doi: 10.1097/01.TP.0000436905.54640.8c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TP.0000436905.54640.8c</ArticleId><ArticleId IdType="pubmed">24162248</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Raemdonck D, Hartwig MG, Hertz MI, Davis RD, Cypel M, Hayes D, et al. Report of the ISHLT working group on primary lung graft dysfunction part IV: prevention and treatment: a 2016 consensus group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36(10):1121&#x2013;1136. doi: 10.1016/j.healun.2017.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2017.07.013</ArticleId><ArticleId IdType="pubmed">28784325</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2&#x2013;3):85&#x2013;118. doi: 10.1016/S0162-3109(00)00188-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0162-3109(00)00188-0</ArticleId><ArticleId IdType="pubmed">10878285</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic-acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993;136(1):5&#x2013;28. doi: 10.1111/j.1600-065X.1993.tb00652.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.1993.tb00652.x</ArticleId><ArticleId IdType="pubmed">7907572</ArticleId></ArticleIdList></Reference><Reference><Citation>Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci. 1993;685(1 Immunomodulat):309&#x2013;329. doi: 10.1111/j.1749-6632.1993.tb35881.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1993.tb35881.x</ArticleId><ArticleId IdType="pubmed">8363235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of Cyclosporin a and FK506. Clin Immunol Immunopathol. 1996;80(3):S45. doi: 10.1006/clin.1996.0140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1996.0140</ArticleId><ArticleId IdType="pubmed">8811062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity. 2000;12(4):359&#x2013;372. doi: 10.1016/S1074-7613(00)80188-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)80188-0</ArticleId><ArticleId IdType="pubmed">10795734</ArticleId></ArticleIdList></Reference><Reference><Citation>Granellipiperno A, Nolan P, Inaba K, Steinman RM. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin-2 promoter. J Exp Med. 1990;172(6):1869&#x2013;1872. doi: 10.1084/jem.172.6.1869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.172.6.1869</ArticleId><ArticleId IdType="pmc">PMC2188759</ArticleId><ArticleId IdType="pubmed">1701825</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143(2):718&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">2472451</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantaleo G, Paolo Rizzardi G, Chapuis AG, Acha-Orbea H, Attinger A, Fleury S, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med. 2000;6(7):762&#x2013;768. doi: 10.1038/77489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/77489</ArticleId><ArticleId IdType="pubmed">10888924</ArticleId></ArticleIdList></Reference><Reference><Citation>Press N, Kimel G, Harris M, Yip B, Craib KJP, Montaner JSG. Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens. HIV clinical trials. 2002;3(1):17&#x2013;20. doi: 10.1310/B6T0-N98J-1J3M-EQPK.</Citation><ArticleIdList><ArticleId IdType="doi">10.1310/B6T0-N98J-1J3M-EQPK</ArticleId><ArticleId IdType="pubmed">11819181</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez V, Fern&#xe1;ndez A, Galeano C, Oliva J, Diez V, Bueno C, et al. Renal transplantation in HIV-infected patients: experience at a tertiary Hospital in Spain and Review of the literature. Transplant Proc. 2013;45(3):1255&#x2013;1259. doi: 10.1016/j.transproceed.2013.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2013.02.032</ArticleId><ArticleId IdType="pubmed">23622672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo Soto JA, de la Rosa RE, del Castillo JL, Morales SC, Olivares EG, Ortega AO, et al. Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients. Transplant Proc. 2003;35(4):1355&#x2013;1359. doi: 10.1016/S0041-1345(03)00364-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0041-1345(03)00364-6</ArticleId><ArticleId IdType="pubmed">12826158</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankatsing SUC, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS. 2004;18(14):1925&#x2013;1931. doi: 10.1097/00002030-200409240-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-200409240-00008</ArticleId><ArticleId IdType="pubmed">15353978</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>